Compare Tesla, Inc. (TSLA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tesla, Inc. vs Zoetis Inc — how do they compare? Tesla, Inc. trades at $328.23 (market cap $1.31T), while Zoetis Inc trades at $73.94 (market cap $31.14B). The key difference: Tesla, Inc. is far larger — about 42.1× Zoetis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| TSLA | ZTS | |
|---|---|---|
Market Cap | $1.31T | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $489.88 | $156.76 |
52-Week Low | $298.16 | $71.91 |
Enterprise Value | $1.29T | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tesla (TSLA) trades at $332.71, up 0.56% on the day, as the stock shows mixed signals with bearish technical indicators but recent positive earnings beats. The company faces declining profit margins (net income margin of 3.67% in 2025) despite steady revenue near $95B, while valuation ratios remain elevated with a P/E of 308. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model.
Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include competitive pressures and high valuation. Analyst consensus price target of $393.87 suggests 18% upside, though technical weakness and earnings volatility warrant caution. Investment opportunity hinges on Tesla's pivot beyond automotive into robotics and energy.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
